Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Phase Ib)

A Phase Ib Study to Evaluate the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Vero Cell)

The purpose of this phase Ib study is to evaluate the safety of a Sabin Inactivated Poliovirus Vaccine (sIPV) in adults and children, and the safety and immunogenicity of it in infants. 20 adults aged 18~45 years and 20 children aged 4 years were only administered one dose of sIPV with high D antigen content. 20 infants aged 2 months (60~90 days) were administered three doses of sIPV with high D antigen content, on the month 0, 1, 2 schedule. Serum samples were collected before the 1st dose and 30 days after the 3rd dose vaccination to assess the immunogenicity in infants. Adverse events occurring within 30 days after each dose were collected to assess the safety.

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Detaljerad beskrivning

The purpose of this phase Ib study is to evaluate the safety of a Sabin Inactivated Poliovirus Vaccine (sIPV) in adults and children, and the safety and immunogenicity of it in infants. 20 adults aged 18~45 years and 20 children aged 4 years were only administered one dose of sIPV with high D antigen content. 20 infants aged 2 months (60~90 days) were administered three doses of sIPV with high D antigen content, on the month 0, 1, 2 schedule. Serum samples were collected before the 1st dose and 30 days after the 3rd dose vaccination to assess the immunogenicity in infants. Adverse events occurring within 30 days after each dose were collected to assess the safety.

The antigen contents of type I, type II and type III polioviruses in the high-dose Sabin IPV were 22 DU, 65 DU and 65 DU. All vaccines were in liquid form, 0.5 ml per dose.

Studietyp

Interventionell

Inskrivning (Faktisk)

60

Fas

  • Fas 2
  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Nanjing, Kina
        • Jiangsu Provincial Center for Disease Control and Prevention

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

1 månad till 45 år (Barn, Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Healthy volunteer aged 18~45 years with/without prior vaccination of poliovirus and without any contraindication for vaccination;
  • Healthy volunteer aged 4 years with/without prior vaccination of poliovirus but without booster vaccination and any contraindication for vaccination;
  • Healthy volunteer aged 2 months (60~90 days) without prior vaccination of poliovirus and any contraindication for vaccination;
  • Guardians of the participants should be capable of understanding the written consent form, and such form should be signed prior to enrolment;
  • Complying with the requirement of the study protocol;
  • Axillary temperature ≤ 37.0 °C;

Exclusion Criteria:

  • Women aged 18~45 years with positive urine pregnancy test, pregnant or lactating women, or women with pregnancy plans within 3 months;
  • Preterm or low birth weight infants;
  • Congenital malformation, developmental disorders, genetic defects, or severe malnutrition;
  • History of polio;
  • Severe nervous system disease (epilepsy, seizures or convulsions) or mental illness;
  • History of allergy to any vaccine, or any ingredient of the vaccine, or serious adverse reaction(s) to vaccination, such as urticaria, dyspnea, angioneurotic edema, abdominal pain, etc;
  • Autoimmune disease or immunodeficiency/immunosuppressive;
  • Bleeding disorder diagnosed by a doctor (e.g., coagulation factor deficiency, coagulation disorder, or platelet disorder), or significant bruising or coagulopathy;
  • Serious chronic diseases, respiratory diseases, cardiovascular diseases, liver or kidney diseases or skin diseases;
  • Mother of the participant has HIV infection;
  • Acute illness or acute exacerbation of chronic disease within the past 7 days;
  • Had a high fever within the past 3 days (axillary temperature ≥ 38.0°C);
  • Receipt of any subunit or inactivated vaccine within the past 7 day;
  • Receipt of any live attenuated vaccine within the past 14 days;
  • Receipt of any blood product within the past 3 months;
  • Any other factor that, in the judgment of the investigator, suggesting the volunteer is unsuitable for this study;

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Experimental Adult Group - High dosage
One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of high dosage investigational sIPV Intervention: Biological: one-dose regimen of high dosage investigational sIPV
The investigational High dosage Sabin IPV was all developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the high dosage Sabin IPV were 22 DU, 65 DU and 65 DU. The vaccine was in liquid form, 0.5 ml per dose.
Experimentell: Experimental Children Group - High dosage
One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of high dosage investigational sIPV Intervention: Biological: one-dose regimen of high dosage investigational sIPV
The investigational High dosage Sabin IPV was all developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the high dosage Sabin IPV were 22 DU, 65 DU and 65 DU. The vaccine was in liquid form, 0.5 ml per dose.
Experimentell: Experimental Infant Group - High dosage
Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of high dosage investigational sIPV Intervention: Biological: Three-dose regimen of high dosage investigational sIPV
The investigational High dosage Sabin IPV was all developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the high dosage Sabin IPV were 22 DU, 65 DU and 65 DU. The vaccine was in liquid form, 0.5 ml per dose.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Serokonversionshastigheterna (SCR) för varje grupp 30 dagar efter tredosregim
Tidsram: 28~42 dagar
Patienter vars preimmuna antikroppsnivå < 1:8 och postimmun antikroppsnivå ≥ 1:8, eller de vars preimmuna antikroppsnivå ≥ 1:8 och ökningen av postimmun antikroppsnivå ≥ 4 gånger anses serokonverterade.
28~42 dagar
The geometric mean titer (GMT) of each group 30 days after three-dose regimen
Tidsram: 28~42 days
GMT of each group 28~42 days after three-dose regimen
28~42 days
The geometric mean fold increase (GMI) of each group 30 days after three-dose regimen
Tidsram: 28~42 days
The GMI is the increase of post-immune GMT from pre-immune GMT
28~42 days

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
The incidences of adverse reactions of each group occurred within 30 days after each injection
Tidsram: 30 days
The number of participants who had adverse reactions divided by the number of all participants
30 days
The incidences of adverse events (AEs) of each group occurred within 30 days after each injection
Tidsram: 30 days
The number of participants who had adverse events (AEs) divided by the number of all participants
30 days

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

24 november 2017

Primärt slutförande (Faktisk)

9 mars 2018

Avslutad studie (Faktisk)

28 december 2018

Studieregistreringsdatum

Först inskickad

9 februari 2020

Först inskickad som uppfyllde QC-kriterierna

9 februari 2020

Första postat (Faktisk)

11 februari 2020

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

11 februari 2020

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

9 februari 2020

Senast verifierad

1 februari 2020

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 2017L00935-1

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera